journal article·2021-12-15

Cascade-Responsive Hierarchical Nanosystems for Multisite Specific Drug Exposure and Boosted Chemoimmunotherapy

Junmei Zhang, Yuanyuan Zhang, Bingbing Zhao, Mengtong Lv, Enping Chen, Changshun Zhao, Linyang Jiang, Hongliang Qian, Dechun Huang, Yinan Zhong, Wei Chen

ACS Applied Materials & Interfaces· Volume 13· Issue 49
Publisher page

Abstract

The precise delivery of multiple drugs to their distinct destinations plays a significant role in safe and efficient combination therapy; however, it is highly challenging to simultaneously realize the targets and overcome the intricate biological hindrances using an all-in-one nanosystem. Herein, a cascade-responsive hierarchical nanosystem containing checkpoint inhibitor anti-PD-L1 antibody (αPD-L1) and paclitaxel (PTX) is developed for spatially programed delivery of multiple drugs and simultaneously overcoming biological pathway barriers. The hierarchical nanoparticles (MPH-NP@A) are composed of pH-sensitive hyaluronic acid-acetal-PTX prodrugs (HA-ace-PTX(SH)) chaperoned by αPD-L1 and metalloproteinase-9 (MMP-9)-responsive outer shells, which could be fast cleaved to release αPD-L1 in the tumor microenvironment (TME). The released αPD-L1 sequentially synergizes with PTX released in the cytoplasm for boosted chemoimmunotherapy due to direct killing of PTX and intensified immune responses through immunogenic cell death (ICD) as well as suppression of immune escape by blocking the PD-1/PD-L1 axis. The in vitro and in vivo studies demonstrate that MPH-NP@A evokes distinct ICD, enhanced cytotoxic T lymphocytes infiltration, as well as significant tumor inhibition, thus providing a promising therapeutic nano-platform for safe and efficient combination therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, China

Engineering Research Center for Smart Pharmaceutical Manufacturing Technologies, Ministry of Education, School of Engineering, China Pharmaceutical University, Nanjing 210009, China

Funding

Government of Jiangsu Province · National Natural Science Foundation of China · Guangdong Province · Nanjing Scientific and Technological Innovation Program for Oversea Talents

References (55)

Show source-provided references
1. 10.1038/nrc.2017.1710.1038/nrc.2017.17 ↗
2. 10.1016/j.addr.2015.11.00710.1016/j.addr.2015.11.007 ↗
3. 10.1016/j.jconrel.2018.12.02010.1016/j.jconrel.2018.12.020 ↗
4. 10.1016/j.addr.2017.04.00710.1016/j.addr.2017.04.007 ↗
5. 10.1016/j.biomaterials.2018.04.02710.1016/j.biomaterials.2018.04.027 ↗
6. 10.1016/j.immuni.2015.11.02410.1016/j.immuni.2015.11.024 ↗
7. 10.1038/nrclinonc.2010.22310.1038/nrclinonc.2010.223 ↗
8. 10.1158/2326-6066.CIR-15-006410.1158/2326-6066.CIR-15-0064 ↗
9. 10.1002/adfm.20200375710.1002/adfm.202003757 ↗
10. 10.1016/j.biomaterials.2020.11990110.1016/j.biomaterials.2020.119901 ↗
11. 10.1016/j.jconrel.2017.11.03710.1016/j.jconrel.2017.11.037 ↗
12. 10.1021/acs.nanolett.1c0097710.1021/acs.nanolett.1c00977 ↗
13. 10.1126/sciadv.abc364610.1126/sciadv.abc3646 ↗
14. 10.1021/acs.nanolett.1c0020910.1021/acs.nanolett.1c00209 ↗
15. 10.1158/1078-0432.CCR-19-354510.1158/1078-0432.CCR-19-3545 ↗
16. 10.1038/nrclinonc.2016.9610.1038/nrclinonc.2016.96 ↗
17. 10.1038/cdd.2013.6710.1038/cdd.2013.67 ↗
18. 10.1038/s41571-020-0413-z10.1038/s41571-020-0413-z ↗
19. 10.1016/j.it.2019.04.00210.1016/j.it.2019.04.002 ↗
20. 10.1038/s41572-020-0160-610.1038/s41572-020-0160-6 ↗
21. 10.1146/annurev.med.57.121304.13124010.1146/annurev.med.57.121304.131240 ↗
22. 10.1038/s41467-019-11235-410.1038/s41467-019-11235-4 ↗
23. 10.1021/acsnano.9b0239510.1021/acsnano.9b02395 ↗
24. 10.1002/adfm.20190244010.1002/adfm.201902440 ↗
25. 10.1002/adfm.20200754410.1002/adfm.202007544 ↗
26. 10.1016/j.biomaterials.2019.11940110.1016/j.biomaterials.2019.119401 ↗
27. 10.1002/anie.20190818510.1002/anie.201908185 ↗
28. 10.1002/anie.20180900610.1002/anie.201809006 ↗
29. 10.1016/j.addr.2017.05.00810.1016/j.addr.2017.05.008 ↗
30. 10.1016/j.addr.2007.06.00310.1016/j.addr.2007.06.003 ↗
31. 10.1002/anie.20191582610.1002/anie.201915826 ↗
32. 10.1038/s41392-020-00342-010.1038/s41392-020-00342-0 ↗
33. 10.1021/acs.nanolett.9b0521010.1021/acs.nanolett.9b05210 ↗
34. 10.1039/D0CS00607F10.1039/D0CS00607F ↗
35. 10.1002/anie.20180760210.1002/anie.201807602 ↗
36. 10.1002/adma.20170117010.1002/adma.201701170 ↗
37. 10.1073/pnas.152208011310.1073/pnas.1522080113 ↗
38. 10.1016/j.biomaterials.2019.11929910.1016/j.biomaterials.2019.119299 ↗
39. 10.1002/smll.20190683210.1002/smll.201906832 ↗
40. 10.1021/acs.nanolett.9b0073710.1021/acs.nanolett.9b00737 ↗
41. 10.1038/s41565-020-0759-510.1038/s41565-020-0759-5 ↗
42. 10.1002/anie.20191104810.1002/anie.201911048 ↗
43. 10.1038/nbt.333010.1038/nbt.3330 ↗
44. 10.1016/j.addr.2019.04.00810.1016/j.addr.2019.04.008 ↗
45. 10.1038/nrd439010.1038/nrd4390 ↗
46. 10.1016/j.cell.2010.03.01510.1016/j.cell.2010.03.015 ↗
47. 10.1016/j.jconrel.2011.01.01710.1016/j.jconrel.2011.01.017 ↗
48. 10.1021/acsnano.7b0805110.1021/acsnano.7b08051 ↗
49. 10.1016/j.biomaterials.2016.01.04910.1016/j.biomaterials.2016.01.049 ↗
50. 10.1038/nbt0207-19210.1038/nbt0207-192 ↗
51. 10.1111/imr.1258210.1111/imr.12582 ↗
52. 10.1146/annurev-immunol-032712-10000810.1146/annurev-immunol-032712-100008 ↗
53. 10.1038/nri159410.1038/nri1594 ↗
54. 10.1021/acs.nanolett.9b0276910.1021/acs.nanolett.9b02769 ↗
55. 10.1016/j.addr.2019.05.00910.1016/j.addr.2019.05.009 ↗